Noriko Nishinarita

发表

CMAR_A_207170 4883..4892

K. Naoki, M. Katagiri, S. Igawa, 2019 .

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study

K. Naoki, M. Katagiri, S. Igawa, 2019, Cancer management and research.

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia

K. Naoki, S. Igawa, Masayuki Shirasawa, 2019, BMC Cancer.

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer

K. Naoki, M. Katagiri, S. Igawa, 2019, PloS one.

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study

K. Naoki, M. Katagiri, S. Igawa, 2019, Thoracic cancer.

Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

K. Naoki, M. Katagiri, S. Igawa, 2018, Cancer management and research.

Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

K. Naoki, M. Katagiri, S. Igawa, 2018, Thoracic cancer.

Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status

K. Naoki, M. Katagiri, S. Igawa, 2018, Oncology.